S-Sibutramine metabolite - Sepracor
Alternative Names: (-)-DDMS; (-)-didesmethylsibutramine - Sepracor; (S)-didesmethylsibutramine - Sepracor; (S)-Sibutramine metabolite - Sepracor; S-DDMS; S-desmethylsibutramine - Sepracor; S-didesmethylsibutramine - SepracorLatest Information Update: 27 Jun 2006
At a glance
- Originator Sepracor
- Class
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Female sexual dysfunction; Male sexual dysfunction
Most Recent Events
- 27 Jun 2006 No development reported - Phase-I for Female sexual dysfunction in USA (unspecified route)
- 27 Jun 2006 No development reported - Phase-II for Male sexual dysfunction in USA (unspecified route)
- 04 Oct 2001 Phase-I clinical trials for Female sexual dysfunction in USA (Unknown route)